Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis

Physiological Research

Volumn 57, Issue 3, 2008, Pages 339-349

  Gallo, Jiri ^a,b   Raska M ^a   Mrazek F ^a   Petek M ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b Faculty of Medicine ^*  (Czech Republic)

Author keywords

Basic multicellular unit; Osteoblast; Osteoclast; Particle disease; Periprosthetic osteolysis

Indexed keywords

EID: 45849119493     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (45)

1. AMBRUZOVÁ Z, GALLO J, MRÁZEK F, KUBIŠTOVÁ Z, ONDERKOVÁ J, PETŘEK M: Association of cytokine gene polymorphisms with the expansive periprosthetic osteolysis in total hip arthroplasty. Tissue Antigens 67: 178, 2006.
2. BLAIR HC, ROBINSON LJ, ZAIDI M: Osteoclast signalling pathways. Biochem Biophys Res Commun 328: 728-738, 2005.
3. BOYCE BF, LI P, YAO Z, ZHANG Q, BADELL IR, SCHWARZ EM, O'KEEFE RJ, XING L: TNF-alpha and pathologic bone resorption. Keio J Med 54: 127-131, 2005.
4. BOYCE BF, SCHWARZ EM, XING L: Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 18: 427-432, 2006.
5. BOYLE WJ, SIMONET WS, LACEY DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
6. CHILDS LM, GOATER JJ, O'KEEFE RJ, SCHWARZ EM: Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 16: 338-347, 2001.
7. FRITZ EA, GLANT TT, VERMES C, JACOBS JJ, ROEBUCK KA: Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris. J Biomed Mater Res A 77: 192-201, 2006.
8. GALLO J, HAVRÁNEK V, ZAPLETALOVÁ J, ČECHOVÁ I: Influence of demographic, surgical and implant variables on wear rate and osteolysis in ABG I hip arthoplasty. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 135-141, 2006.
9. GARRIGUES GE, CHO DR, RUBASH HE, GOLDRING SR, HERNDON JH, SHANBHAG AS: Gene expression clustering using self-organizing maps: analysis of the macrophage response to particulate biomaterials. Biomaterials 26: 2933-2945, 2005.
10. GUENTHER R, MORAWIETZ L, FRIEDERICH M, GEHRKE T, FROMMELT L, SCHRODER JH, KRENN V: Expression of CD9, CD11b, CD18, CD52 and PDGFR-beta in the interface membrane of loose endoprostheses. Pathol Res Pract 201: 435-442, 2005.
11. HARRIS WH: Osteolysis and particle disease in hip replacement. A review. Acta Orthop Scand 65: 113-123, 1994.
12. HOLDING CA, FINDLAY DM, STAMENKOV R, NEALE SD, LUCAS H, DHARMAPATNI AS, CALLARY SA, SHRESTHA KR, ATKINS GJ, HOWIE DW, HAYNES DR: The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27: 5212-5219, 2006.
13. KONTTINEN YT, XU JW, WARIS E, LI TF, GOMEZ-BARRENA E, NORDSLETTEN L, SANTAVIRTA S: Interleukin-6 in aseptic loosening of total hip replacement prostheses. Clin Exp Rheumatol 20: 485-490, 2002.
14. KORENY T, TUNYOGI-CSAPO M, GAL I, VERMES C, JACOBS JJ, GLANT TT: The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 54: 3221-3232, 2006.
15. KRISHNAN V, BRYANT HU, MACDOUGALD OA: Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209, 2006.
16. LEE SK, LORENZO J: Cytokines regulating osteoclast formation and function. Curr Opin Rheumatol 18: 411-418, 2006.
17. LI TF, SANTAVIRTA S, WARIS V, LASSUS J, LINDROOS L, XU JW, VIRTANEN I, KONTTINEN YT: No lymphokines in T-cells around loosened hip prostheses. Acta Orthop Scand 72: 241-247, 2001.
18. MA G, AINOLA M, LILJESTROM M, SANTAVIRTA S, PODUVAL P, ZHAO D, CHEN T, KONTTINEN YT: Increased expression and processing of ADAM 12 (meltrin-alpha) in osteolysis associated with aseptic loosening of total hip replacement implants. J Rheumatol 32: 1943-1950, 2005.
19. MALIK MH, BAYAT A, JURY F, OLLIER WE, KAY PR: Genetic susceptibility to hip arthroplasty failure-association with the RANK/OPG pathway. Int Orthop 30: 177-181, 2006.
20. MANDELIN J, LI TF, LILJESTROM M, KROON ME, HANEMAAIJER R, SANTAVIRTA S, KONTTINEN YT: Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br 85: 1196-1201, 2003.
21. MANDELIN J, LI TF, HUKKANEN M, LILJESTROM M, SALO J, SANTAVIRTA S, KONTTINEN YT: Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J Rheumatol 32: 713-720, 2005.
22. MARTIN TJ, SIMS NA: Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11: 76-81, 2005.
23. MCKELLOP HA, CAMPBELL P, PARK SH, SCHMALZRIED TP, GRIGORIS P, AMSTUTZ HC, SARMIENTO A: The origin of submicron polyethylene wear debris in total hip arthroplasty. Clin Orthop Relat Res 311: 3-20, 1995.
24. NALEPKA JL, LEE MJ, KRAAY MJ, MARCUS RE, GOLDBERG VM, CHEN X, GREENFIELD EM: Lipopolysaccharide found in aseptic loosening of patients with inflammatory arthritis. Clin Orthop Relat Res 451: 229-235, 2006.
25. PARFITT AM: Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30: 5-7, 2002.
26. POKORNÝ D, ŠLOUF M, HORÁK Z, JAHODA D, ENTLICHER G, EKLOVÁ S, SOSNA A: Method for assessment of distribution of UHMWPE wear particles in periprosthetic tissues in total hip arthroplasty. Acta Chir Orthop Traumatol Cech 73: 243-250, 2006.
27. PURDUE PE, KOULOUVARIS P, POTTER HG, NESTOR BJ, SCULCO TP: The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res, in press, 2006.
28. RAKSHIT DS, LY K, SENGUPTA TK, NESTOR BJ, SCULCO TP, IVASHKIV LB, PURDUE PE: Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. J Bone Joint Surg Am 88: 788-799, 2006.
29. REVELL PA, JELLIE SE: Interleukin 15 production by macrophages in the implant interface membrane of aseptically loosened joint replacements. J Mater Sci Mater Med 9: 727-730, 1998.
30. SHANBHAG AS: Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 14: 215-225, 2006.
31. SIMS N, BARON R: Bone: structure, function, growth, and remodeling. In: Orthopaedics. RH FITZGERALD Jr, H KAUFER, AL MALKANI (eds), Mosby, St. Louis, 2002, pp 147-159.
32. STAINS JP, CIVITELLI R: Cell-to-cell interactions in bone. Biochem Biophys Res Commun 328: 721-727, 2005.
33. STANLEY KT, VANDORT C, MOTYL C, ENDRES J, FOX DA: Immunocompetent properties of human osteoblasts: interactions with T lymphocytes. J Bone Miner Res 21: 29-36, 2006.
34. SUNDFELDT M, CARLSSON LV, JOHANSSON CB, THOMSEN P, GRETZER C: Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop 77: 177-197, 2006.
35. TAKI N, TATRO JM, NALEPKA JL, TOGAWA D, GOLDBERG VM, RIMNAC CM, GREENFIELD EM: Polyethylene and titanium particles induce osteolysis by similar, lymphocyte-independent, mechanisms. J Orthop Res 23: 376-383, 2005.
36. TANAKA Y, NAKAYAMADA S, OKADA Y: Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4: 325-328, 2005.
37. VEIGL D, NIEDERLOVÁ J, KRYŠTŮFKOVÁ O: Periprosthetic osteolysis and its association with the molecule RANKL expression. Physiol Res 56: 455-462, 2007.
38. VON KNOCH F, HECKELEI A, WEDEMEYER C, SAXLER G, HILKEN G, BRANKAMP J, STERNER T, LANDGRAEBER S, HENSCHKE F, LOER F, VON KNOCH M: Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. J Biomed Mater Res A 75: 288-294, 2005.
39. WILKINSON JM, WILSON AG, STOCKLEY I, SCOTT IR, MACDONALD DA, HAMER AJ, DUFF GW, EASTELL R: Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. J Bone Miner Res 18: 1995-2001, 2003.
40. WILKINSON JM, HAMER AJ, STOCKLEY I, EASTELL R: Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Orthop Res 23: 520-525, 2005.
41. WILLERT HG, BUCHHORN GH, FAYYAZI A, FLURY R, WINDLER M, KOSTER G, LOHMANN CH: Metal-onmetal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg Am 87: 28-36, 2005.
42. XING L, BOYCE BF: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 328: 709-720, 2005.
43. YANG SY, WU B, MAYTON L, MUKHERJEE P, ROBBINS PD, EVANS CH, WOOLEY PH: Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis. Gene Ther 11: 483-491, 2004.
44. YEUNG RSM: Bones, blood vessels, and the immune system: what's the link? J Rheumatol 32: 2072-2074, 2005.
45. ZHANG Q, BADELL IR, SCHWARZ EM, BOULUKOS KE, YAO Z, BOYCE BF, XING L: Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 52: 2708-2718, 2005.